News | September 19, 2012

First Atrial Fibrillation Patient Treated With Innovative Ablation Procedure

September 19, 2012 — This past week, surgeons and cardiologists at Sentara Heart Hospital were the first in the world to begin performing surgeries in the Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study (Staged DEEP) feasibility trial. Cardiothoracic surgeon collaborator Jonathan Philpott, M.D., director of the Sentara Atrial Fibrillation Surgery Program, and cardiac electrophysiologist collaborator Ian Woollett, M.D., of Cardiovascular Associates, performed the first procedure.

The Staged DEEP trial is a U.S. Food and Drug Administration (FDA)-approved pilot study sponsored by cardiac device manufacturer AtriCure Inc. The study is designed to evaluate the safety and efficacy of a combined procedure whereby the surgeon creates lines of block on the outside of the heart, working through tiny chest incisions. During the same hospital stay, an electrophysiologist tests the surgical lines and then completes additional ablation lines using tiny catheters within the heart. There are currently no FDA-approved devices for the minimally invasive surgical (MIS) or endocardial treatment of persistent forms of AF, and current options yield very limited success.

"We believe that this staged hybrid procedure has the potential to represent an important advancement in the treatment of persistent forms of AF," said Robert Bernstein, M.D., an electrophysiologist in Norfolk, Va., and one of four electrophysiologists at Sentara collaborating in the trial. "Our initial experience with this hybrid procedure suggests that it represents a highly promising AF treatment."

AF is the most common irregular heartbeat affecting more than 2 million people in the United States. It is characterized by heart palpitations, dizziness and shortness of breath. Persistent forms of AF comprise roughly half of the AF patient population, and this number is expected to increase significantly due to the progressive nature of the disease and the aging population.

Said Philpott: “Our preliminary experience with this procedure is very encouraging. The partnership between the electrophysiologist and the cardiac surgeon in the hybrid procedure leverages the skills and technologies of each specialist, providing patients with the most comprehensive ablation and mapping procedure available.”

“Staging these procedures gives the cardiac surgeon and the electrophysiologist the flexibility to work within their own familiar environments, making each team more efficient and effective,” added Woollett

For more information:

Related Content

First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
FDA Approves Biosense Webster's Tag-Index Guided Ablation Software
Technology | Ablation Systems | October 09, 2018
Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA) for its Visitag...
Medtronic Cryoballoon Improves Quality of Life, Reduces Systems of Persistent Atrial Fibrillation
News | Ablation Systems | August 28, 2018
Medtronic plc announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life...
Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter
News | Ablation Systems | August 02, 2018
Thermedical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device...
Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously.  #HRS2018

The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously. 

News | Ablation Systems | May 21, 2018
May 21, 2018 — Complete pulmonary vein isolation (PVI) was achieved in more than 99 percent of patients in a first-in
Overlay Init